Description
Thymopentin is a synthetic, immunomodulatory pentapeptide (thymopoietin, 32-36). In animal models of experimental autoimmune encephalitis (EAE), thymopentin decreases phosphorylation of IκB kinase and inhibits production of HSP72, lessening disease severity. In other models, thymopentin decreases iNOS expression and activity, exhibiting potential anticancer chemotherapeutic benefit in the treatment of Sezary syndrome. In macrophages, this compound increases activation of NF-κB. In other in vitro models, thymopentin binds to MHC II HLA-DR complexes and modulates T cell activity.
References
Lunin SM, Glushkova OV, Khrenov MO, et al. Thymic peptides restrain the inflammatory response in mice with experimental autoimmune encephalomyelitis. Immunobiology. 2013 Mar;218(3):402-7. PMID: 22727332.
Patruno A, Tosco P, Borretto E, et al. Thymopentin down-regulates both activity and expression of iNOS in blood cells of Sézary syndrome patients. Nitric Oxide. 2012 Oct 15;27(3):143-9. PMID: 22721692.
Lunin SM, Glushkova OV, Khrenov MO, et al. Thymus peptides regulate activity of RAW 264.7 macrophage cells: inhibitory analysis and a role of signal cascades. Expert Opin Ther Targets. 2011 Dec;15(12):1337-46. PMID: 22148922.
Liu Z, Zheng X, Wang J, et al. Molecular analysis of thymopentin binding to HLA-DR molecules. PLoS One. 2007 Dec 26;2(12):e1348. PMID: 18159232.
